Paolo Sfriso

About Paolo Sfriso

Paolo Sfriso, With an exceptional h-index of 45 and a recent h-index of 30 (since 2020), a distinguished researcher at Università degli Studi di Padova, specializes in the field of rheumatology.

His recent articles reflect a diverse array of research interests and contributions to the field:

Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registry

The systemic score may identify life‐threatening evolution in Still's disease: data from the GIRRCS AOSD‐study group and the AIDA Network Still's Disease Registry

Adult-Onset Still’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options

Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort

Correction: Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry

Pulmonary alveolar proteinosis in an adult patient affected by Still's disease and recurrent episodes of macrophage activation syndrome

Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission

Autoinflammatory Diseases and COVID-19 Vaccination: Analysis of SARS-CoV-2 Anti-S-RBD IgG Levels in a Cohort of Patients Receiving IL-1 Inhibitors

Paolo Sfriso Information

University

Position

___

Citations(all)

6590

Citations(since 2020)

2609

Cited By

5648

hIndex(all)

45

hIndex(since 2020)

30

i10Index(all)

100

i10Index(since 2020)

73

Email

University Profile Page

Google Scholar

Paolo Sfriso Skills & Research Interests

rheumatology

Top articles of Paolo Sfriso

Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registry

Seminars in Arthritis and Rheumatism

2024/6/1

Adult-Onset Still’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options

2024/3/5

Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort

American Journal of Hematology

2024/2

Pulmonary alveolar proteinosis in an adult patient affected by Still's disease and recurrent episodes of macrophage activation syndrome

Joint Bone Spine

2024

Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission

2023/7/22

Autoinflammatory Diseases and COVID-19 Vaccination: Analysis of SARS-CoV-2 Anti-S-RBD IgG Levels in a Cohort of Patients Receiving IL-1 Inhibitors

Journal of Clinical Medicine

2023/7/18

IL-18 in Autoinflammatory Diseases: Focus on Adult Onset Still Disease and Macrophages Activation Syndrome

2023/7/5

AB1307 ANALYSIS OF ANTI-SARS-CoV-2 S-RBD IGG ANTIBODY LEVELS IN A COHORT OF PATIENTS RECEIVING IL-1 INHIBITORS

2023/6/1

POS1578 JAK INHIBITORS AND VEXAS SYNDROME: A SUCCESSFULLY CASE TREATED WITH FILGOTINIB

2023/6/1

Sex-dependent PD-L1/sPD-L1 trafficking in human endothelial cells in response to inflammatory cytokines and VEGF

Biomedicine & Pharmacotherapy

2023/6/1

Francesca Oliviero
Francesca Oliviero

H-Index: 24

Paolo Sfriso
Paolo Sfriso

H-Index: 30

Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): A CARTOGRAPHY OF UBA1 GENE TESTING, EPIDEMIOLOGY AND CLINICAL-GENOMIC CHARACTERISTICS …

Leukemia Research

2023/5/1

Leucocyte abnormalities in synovial fluid of degenerative and inflammatory arthropathies

International Journal of Molecular Sciences

2023/3/13

JAK inhibitors for the treatment of VEXAS syndrome

2023/3

Intravenous anakinra to curb cytokine storm in adult-onset Still's disease and in macrophage activation syndrome: a case series

Joint Bone Spine

2023/3/1

New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort

Clin Exp Rheumatol

2023/3

THE ADVANTAGES OF NEXT GENERATION SEQUENCING FOR CORRECTLY DIAGNOSING RARE RHEUMATIC AUTOINFLAMMATORY DISEASES: A SINGLE-CENTER STUDY

CLINICAL CHEMISTRY AND LABORATORY MEDICINE

2023

Efficacy of canakinumab in patients with Still’s disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still’s Disease

Frontiers in Medicine

2023/12/12

See List of Professors in Paolo Sfriso University(Università degli Studi di Padova)

Co-Authors

academic-engine